IL134288A0 - TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6 - Google Patents

TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6

Info

Publication number
IL134288A0
IL134288A0 IL13428898A IL13428898A IL134288A0 IL 134288 A0 IL134288 A0 IL 134288A0 IL 13428898 A IL13428898 A IL 13428898A IL 13428898 A IL13428898 A IL 13428898A IL 134288 A0 IL134288 A0 IL 134288A0
Authority
IL
Israel
Prior art keywords
fibrosis
ανβ6
antagonists
treatment
lung injury
Prior art date
Application number
IL13428898A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL134288A0 publication Critical patent/IL134288A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13428898A 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6 IL134288A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
PCT/US1998/016439 WO1999007405A1 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6

Publications (1)

Publication Number Publication Date
IL134288A0 true IL134288A0 (en) 2001-04-30

Family

ID=21995323

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13428898A IL134288A0 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6
IL134288A IL134288A (en) 1997-08-08 2000-01-30 Using an antibody that binds integrin alpha V beta 6 to prepare a drug to treat renal failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL134288A IL134288A (en) 1997-08-08 2000-01-30 Using an antibody that binds integrin alpha V beta 6 to prepare a drug to treat renal failure

Country Status (23)

Country Link
US (5) US20020004482A1 (cs)
EP (3) EP1930022B1 (cs)
JP (2) JP2001513333A (cs)
KR (1) KR100586202B1 (cs)
CN (1) CN1267224A (cs)
AT (3) ATE286742T1 (cs)
AU (1) AU739283B2 (cs)
BR (1) BR9814040A (cs)
CA (1) CA2297736A1 (cs)
CY (2) CY1110462T1 (cs)
CZ (1) CZ299768B6 (cs)
DE (2) DE69828614T2 (cs)
DK (2) DK1930022T3 (cs)
EE (1) EE04752B1 (cs)
ES (3) ES2364703T3 (cs)
HU (1) HU228900B1 (cs)
IL (2) IL134288A0 (cs)
NZ (2) NZ515955A (cs)
PL (2) PL201716B1 (cs)
PT (3) PT996460E (cs)
RU (1) RU2221589C2 (cs)
TR (2) TR200000374T2 (cs)
WO (1) WO1999007405A1 (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
PT996460E (pt) * 1997-08-08 2005-04-29 Univ California Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6
KR100746522B1 (ko) * 1999-04-22 2007-08-07 바이오겐 아이덱 엠에이 인코포레이티드 인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
ES2671522T3 (es) * 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
JP5362563B2 (ja) * 2006-08-03 2013-12-11 アストラゼネカ・アクチエボラーグ αＶβ６に対する抗体およびその使用
EP2087008A1 (en) * 2006-10-19 2009-08-12 The Regents of the University of California TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
AU2010275367B2 (en) 2009-07-24 2015-09-03 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avB5 integrin
WO2011022667A2 (en) 2009-08-21 2011-02-24 Arresto Biosciences, Inc Catalytic domains from lysyl oxidase and loxl2
BR112012008111A2 (pt) * 2009-08-21 2017-02-21 Gilead Biologics Inc métodos e composições para tratamento de desordens fibróticas pulmonares
MX2012009088A (es) * 2010-02-04 2012-12-05 Gilead Biologics Inc Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
AU2013221585B2 (en) 2012-02-17 2017-03-30 Seagen Inc. Antibodies to integrin alphavbeta6 and use of same to treat cancer
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
MA49948A (fr) 2017-08-22 2020-07-01 Biogen Ma Inc Compositions pharmaceutiques et schémas posologiques contenant des anticorps anti-alpha (v) bêta (6)
US11827709B2 (en) 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
MX2022013753A (es) * 2020-05-07 2023-01-30 Pliant Therapeutics Inc Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
DE68926051T2 (de) 1988-12-20 1996-08-29 Jolla Cancer Res Found Polypeptid-polymer-konjugate mit wundheilender wirkung
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
DK0719859T3 (da) * 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
PT996460E (pt) * 1997-08-08 2005-04-29 Univ California Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6

Also Published As

Publication number Publication date
EP1504764B1 (en) 2008-10-08
US6316601B1 (en) 2001-11-13
ATE511850T1 (de) 2011-06-15
EE200000068A (et) 2000-10-16
US20020004482A1 (en) 2002-01-10
ATE410179T1 (de) 2008-10-15
TR200202323T2 (tr) 2002-12-23
PL341029A1 (en) 2001-03-26
JP2001513333A (ja) 2001-09-04
EP1930022B1 (en) 2011-06-08
US20040208878A1 (en) 2004-10-21
PL201716B1 (pl) 2009-05-29
BR9814040A (pt) 2000-10-03
IL134288A (en) 2008-07-08
WO1999007405A1 (en) 1999-02-18
HUP0003547A2 (hu) 2001-02-28
NZ515955A (en) 2003-04-29
EP0996460A4 (en) 2001-03-07
CY1110462T1 (el) 2015-04-29
EP0996460B1 (en) 2005-01-12
ATE286742T1 (de) 2005-01-15
CZ2000413A3 (cs) 2000-11-15
US7544358B2 (en) 2009-06-09
ES2311131T3 (es) 2009-02-01
HUP0003547A3 (en) 2002-05-28
CA2297736A1 (en) 1999-02-18
DE69840113D1 (de) 2008-11-20
DE69828614D1 (de) 2005-02-17
ES2364703T3 (es) 2011-09-12
ES2235350T3 (es) 2005-07-01
CZ299768B6 (cs) 2008-11-19
JP2009001587A (ja) 2009-01-08
PT996460E (pt) 2005-04-29
NZ502546A (en) 2002-02-01
KR20010022740A (ko) 2001-03-26
EE04752B1 (et) 2006-12-15
DK1930022T3 (da) 2011-07-25
PT1930022E (pt) 2011-08-01
AU739283B2 (en) 2001-10-11
US20010056076A1 (en) 2001-12-27
TR200000374T2 (tr) 2000-09-21
PL199014B1 (pl) 2008-08-29
CN1267224A (zh) 2000-09-20
DE69828614T2 (de) 2006-02-09
PT1504764E (pt) 2009-01-14
AU8774398A (en) 1999-03-01
HU228900B1 (en) 2013-06-28
RU2221589C2 (ru) 2004-01-20
KR100586202B1 (ko) 2006-06-07
US20070148173A1 (en) 2007-06-28
EP0996460A1 (en) 2000-05-03
EP1504764A1 (en) 2005-02-09
DK1504764T3 (da) 2008-11-17
EP1930022A1 (en) 2008-06-11
CY1111792T1 (el) 2015-10-07
US7150871B2 (en) 2006-12-19
US6692741B2 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
IL134288A0 (en) TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6
SI1007089T1 (sl) Antikoagulantska humanizirana protitelesa proti faktorju IX za uporabo pri zdravljenju tromboze
LV11868A (lv) Kermena svara modulatori to pielietojums diagnostika un terapija
DE69911221D1 (de) Methode und gerät zur darreichung von therapeutischen mitteln in verbindung mit dem plazieren von radioaktiven körnern
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
IL117993A0 (en) Modified anti-icam-1 antibodies and their use in the treatment of inflammation
ZA956005B (en) Iron-containing nanoparticles their production and their use for diagnostic and therapeutic purposes
FI964341A7 (fi) Prosessi ja laitteisto, joilla vähennetään kehon tietyissä kohdissa ol evaa rasvakudosta yhdistetyllä lämpökäsittelyllä ja lihastoiminnalla
FI961083L (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
IL128644A0 (en) Use of a combination of amoxycillin and clavulanate in the manufacture of a medicament for the treatment of drug-resistant streptococcus pneumonia
PL371770A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
AU2140492A (en) Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
HUP0001063A3 (en) Use of green porphyrins in the manufacture of a medicament treating atherosclerosis
AU5127098A (en) Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
NO994165D0 (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
ZA921292B (en) Treatment of lower urinary tract disorders.
ZA913497B (en) Azabenzimidazoles in the treatment of asthma,arthritis and related diseases
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
AU5659798A (en) Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury
WO1997033620A3 (de) Verbindungen zur behandlung von tumoren
PL328924A1 (en) Method of treating abuse of substances
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence
Goodnough Mechanisms of action of selected drug therapies used in the treatment of refractory depression
RU98114654A (ru) Способ лечения туберкулеза легких
ZA9510197B (en) Dtpa derivatives substituted in a novel way, their metal complexes, pharmaceutical agents that contain these complexes and their use in diagnosis and therapy

Legal Events

Date Code Title Description
KB Patent renewed